Prognostic and therapeutic advances based on molecular features included, for example, identifying the estrogen and progesterone receptor and HER2/Neu status of breast cancers, or the mutational status of gastric stromal sarcomas and response to Gleevec [1]. This evidence concerns the gene ERBB2 and breast carcinoma.